Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real life

Journal of Viral Hepatitis

Volumn 23, Issue 12, 2016, Pages 950-954

  Willemse, S B ^a   Baak, L C ^b   Kuiken, S D ^b   van der Sluys Veer, A ^b   Lettinga, K D ^b   van der Meer, J T M ^a   Depla, A C T M ^c   Tuynman, H ^c   van Nieuwkerk, C M J ^d   Schinkel, C J ^a   Kwa, D ^b   Reesink, H W ^a   van der Valk, M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^c SLOTERVAART HOSPITAL   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

direct acting antivirals (DAAs); HCV genotype 4; simeprevir; sofosbuvir

Indexed keywords

RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; ANTIVIRUS AGENT; PROTEINASE INHIBITOR;

ADULT; ADVANCED FIBROSIS; AGED; ARTICLE; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; HUMAN CELL; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NETHERLANDS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SUSTAINED VIRAL RESPONSE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; VIRAL PHENOMENA AND FUNCTIONS; VIROLOGICAL RELAPSE; CLASSIFICATION; CLINICAL TRIAL; COMPLICATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; RECURRENT DISEASE; TREATMENT OUTCOME; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NETHERLANDS; PROTEASE INHIBITORS; RECURRENCE; RETROSPECTIVE STUDIES; SIMEPREVIR; SOFOSBUVIR; TREATMENT OUTCOME;

EID: 84993660588     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12567     Document Type: Article

References (21)

1. Saito I, Miyamura T, Ohbayashi A, et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci USA 1990;87:6547–6549.
2. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61:S45–S57.
3. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2014. J Hepatol. 2014;61:373–395.
4. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014;384:1756–1765 Erratum in: Lancet 2014; 384:1748.
5. Jacobson I, Ghalib RH, Rodriguez-Torres M, et al. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naïve and prior null responder patients: the COSMOS study. Hepatology 2013;58:1379A.
6. Gutierrez JA, Carrion AF, Avalos D, et al. Sofosbuvir and simeprevir for treatment of Hepatitis C Virus infection in liver transplant recipients. Liver Transpl. 2015;21:823–830.
7. Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014;384:403–413.
8. Forns X, Lawitz E, Zeuzem S, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014;146:1669–1679.e3.
9. Manns M, Marcellin P, Poordad F, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014;384:414–426.
10. Moreno C, Hezode C, Marcellin P, et al. Once-daily simeprevir (TMC435) with peginterferon/ribavirin in treatment-naive or treatment-experienced chronic HCV genotype 4-infected patients: final results of a phase III trial. J Hepatol. 2014;60(Suppl1):S535.
11. Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013;381:2100–2107.
12. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878–1887.
13. Ruane PJ, Ain D, Meshrekey R, et al. Sofosbuvir plus ribavirin, an interferon-free regimen, in the treatment of treatment-naive and treatment-experienced patients with chronic genotype 4 HCV infection. J Hepatol. 2014;60(Suppl1):S503–S504.
14. Berden F, Van Tilborg M, Arends JE, et al. Dutch guidance for treatment of hepatitis C infection. www.HCVrichtsnoer.nl. Accessed 14 January 2016.
15. Lawitz E, Matusow G, DeJesus E, et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a Phase 3 study (OPTIMIST-2). Hepatology 2016. [Epub ahead of print].
16. Sulkowski MS, Vargas HE, Di Bisceglie AM, et al. HCV-TARGET Study Group. Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection. Gastroenterology 2016;150:419–429
17. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696–699.
18. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996;24:289–293.
19. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513–1520.
20. Pyne MT, Hillyard DR. Evaluation of the Roche COBAS AmpliPrep/COBAS TaqMan HCV Test. Diagn Microbiol Infect Dis. 2013;77:25–30.
21. Wiesmann F, Naeth G, Sarrazin C, et al. Variation analysis of six HCV viral load assays using low viremic HCV samples in the range of the clinical decision points for HCV protease inhibitors. Med Microbiol Immunol. 2015;204:515–525.